Viread leads outpatient prescription market last July, chased by Lipitor
While Gilead Sciences’ Viread was rushing at the top in the outpatient prescription market last July, Lipitor was chasing after it. Among the top 15 medicines, in addition, Chong Kun Dang’s Gliatilin and Daewoong Bio’s Gliatamin, the two products, recorded a double-digit growth rate.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.